Daclatasvir dihydrochloride
| CAS No. | 1009119-65-6 | Cat. No. | BCP13025 |
| Name | Daclatasvir dihydrochloride | ||
| Synonyms | Daclatasvir 2HCl;BMS-790052 dihydrochloride;BMS790052 dihydrochloride;BMS 790052 dihydrochloride; EBP883; EBP 883; EBP-883; | ||
| Formula | C40H52Cl2N8O6 | M. Wt | 811.8 |
| Description | Daclatasvir is NS5A inhibitor and a drug for the treatment of hepatitis C (HCV). It is was developed by Bristol-Myers Squibb and was approved in Europe on 22 August 2014. Daclatasvir inhibits the HCV nonstructural protein NS5A. Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA. Daclatasvir has been tested in combination regimens with pegylated interferon and ribavirin, as well as with other direct-acting antiviral agents including asunaprevir and sofosbuvir. | ||
| Pathways | Protease/Metabolic Enzyme Microbiology/Virology | ||
| Targets | HCV Protease HCV | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.